Epoch 14: Analyzing Biotech Press Releases

Reading between the lines, Understanding biotech data, When good means bad

Welcome to the 15 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,105 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. This week we discuss the topic of analyzing biotech press releases. People are asking us all the time how a biotech company can have a positive press release and the stock price craters. Today we share with you how to interpret these press releases and provide tips for reading between the lines.

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts.  This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences.  We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction.  Be sure to SUBSCRIBE to not miss.

Enough shilling for the day, lots to cover this week, let's get started!